NTCP opens the door for hepatitis B virus infection.
暂无分享,去创建一个
[1] R. Lanford,et al. Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion , 1993, Journal of virology.
[2] B. Autran,et al. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.
[3] H. Varmus,et al. The molecular biology of the hepatitis B viruses. , 1987, Annual review of biochemistry.
[4] Sean Ekins,et al. Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[5] Hussein H. Aly,et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. , 2014, Biochemical and biophysical research communications.
[6] R. Schwabe,et al. Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes , 2022 .
[7] C. Sureau,et al. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle. , 2014, Antiviral research.
[8] Y. Ni,et al. Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction , 2009, Journal of Virology.
[9] A. Neurath,et al. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. , 1989, Vaccine.
[10] J. Mullins,et al. Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA , 1986, Cell.
[11] Wenhui Li,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.
[12] Vyas Ramanan,et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems , 2014, Proceedings of the National Academy of Sciences.
[13] M. Fälth,et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. , 2014, Gastroenterology.
[14] C. Bréchot,et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide , 1988, Journal of virology.
[15] M. Tao,et al. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. , 2014, Antiviral research.
[16] A. Lok,et al. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. , 2015, Journal of hepatology.
[17] P. Galle,et al. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. , 1993, Virology.
[18] M. Sugiyama,et al. Dysregulation of Retinoic Acid Receptor Diminishes Hepatocyte Permissiveness to Hepatitis B Virus Infection through Modulation of Sodium Taurocholate Cotransporting Polypeptide (NTCP) Expression* , 2014, The Journal of Biological Chemistry.
[19] C. Ryu,et al. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. , 2004, Virology.
[20] S. Urban,et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. , 2005, Gastroenterology.
[21] A. Lohse,et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism , 2014, Hepatology.
[22] Christian Trepo,et al. Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[23] B. Stieger. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. , 2011, Handbook of experimental pharmacology.
[24] M. Tschapka,et al. Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes , 2013, Proceedings of the National Academy of Sciences.
[25] J. Taylor,et al. Hepatitis delta virus. , 2006, Virology.
[26] D. Glebe,et al. Role of glycosaminoglycans for binding and infection of hepatitis B virus , 2007, Cellular microbiology.
[27] C. Guguen-Guillouzo,et al. Infection Process of the Hepatitis B Virus Depends on the Presence of a Defined Sequence in the Pre-S1 Domain , 1999, Journal of Virology.
[28] S. Urban,et al. Viral and cellular determinants involved in hepadnaviral entry. , 2007, World journal of gastroenterology.
[29] S. Urban,et al. Hepatitis B virus infection initiates with a large surface protein–dependent binding to heparan sulfate proteoglycans , 2007 .
[30] Wenhui Li,et al. Sodium Taurocholate Cotransporting Polypeptide Mediates Woolly Monkey Hepatitis B Virus Infection of Tupaia Hepatocytes , 2013, Journal of Virology.
[31] R. Gish,et al. Chronic hepatitis B: what should be the goal for new therapies? , 2013, Antiviral research.
[32] V. Lohmann,et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. , 2014, Journal of hepatology.
[33] U. Protzer,et al. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. , 2013, Antiviral research.
[34] M. Anwer,et al. Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters , 2013, Pflügers Archiv - European Journal of Physiology.
[35] S. Urban,et al. Efficient Inhibition of Hepatitis B Virus Infection by Acylated Peptides Derived from the Large Viral Surface Protein , 2004, Journal of Virology.
[36] Seungtaek Kim,et al. The FDA-Approved Drug Irbesartan Inhibits HBV-Infection in HepG2 Cells Stably Expressing Sodium Taurocholate Co-Transporting Polypeptide , 2015, Antiviral therapy.
[37] U. Beuers,et al. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na+-taurocholate cotransporting polypeptide knockout mice , 2015, Hepatology.
[38] Thomas Lütteke,et al. The SLC10 carrier family: transport functions and molecular structure. , 2012, Current topics in membranes.
[39] S. Chi,et al. Pre‐structured motifs in the natively unstructured preS1 surface antigen of hepatitis B virus , 2007, Protein science : a publication of the Protein Society.
[40] M. Quick,et al. Structural basis of the alternating-access mechanism in a bile acid transporter , 2013, Nature.
[41] H. Waterham,et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype , 2015, Hepatology.
[42] C. Seeger,et al. Molecular biology of hepatitis B virus infection. , 2015, Virology.
[43] C. Sureau,et al. The Pre-S1 and Antigenic Loop Infectivity Determinants of the Hepatitis B Virus Envelope Proteins Are Functionally Independent , 2009, Journal of Virology.
[44] H. Kusuhara,et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP) , 2014, Hepatology.
[45] U. Haberkorn,et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein , 2008, Nature Biotechnology.
[46] O. Fardel,et al. Interleukin 6 inhibits HBV entry through NTCP down regulation. , 2015, Virology.
[47] U. Haberkorn,et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts , 2013, Hepatology.
[48] R. Lanford,et al. Mapping of the Hepatitis B Virus Pre-S1 Domain Involved in Receptor Recognition , 2005, Journal of Virology.
[49] T. Weiss,et al. Myristoylated PreS1‐domain of the hepatitis B virus L‐protein mediates specific binding to differentiated hepatocytes , 2013, Hepatology.
[50] Wenhui Li,et al. Molecular Determinants of Hepatitis B and D Virus Entry Restriction in Mouse Sodium Taurocholate Cotransporting Polypeptide , 2013, Journal of Virology.
[51] P. Meier,et al. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. , 1994, The Journal of clinical investigation.
[52] H. Alter,et al. Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[53] C. Ryu,et al. Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1. , 2000, Virology.
[54] G. Acs,et al. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[55] C. Sureau,et al. Infectivity Determinants of the Hepatitis B Virus Pre-S Domain Are Confined to the N-Terminal 75 Amino Acid Residues , 2007, Journal of Virology.
[56] Wenhui Li,et al. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide , 2015, PLoS pathogens.
[57] Olivier Fardel,et al. Regulation of Drug Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokines Tumor Necrosis Factor-α or Interleukin-6 , 2009, Drug Metabolism and Disposition.
[58] O. Fardel,et al. Regulation of drug transporter expression by oncostatin M in human hepatocytes. , 2011, Biochemical pharmacology.
[59] M. Schnölzer,et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site , 2006, Hepatology.
[60] J. Polli,et al. A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. , 2015, International journal of pharmaceutics.
[61] C. Sureau,et al. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus A‐determinant , 2013, Hepatology.
[62] W. Gerlich,et al. Pre-S1 Antigen-Dependent Infection of Tupaia Hepatocyte Cultures with Human Hepatitis B Virus , 2003, Journal of Virology.
[63] H. Blum,et al. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo , 1996, Hepatology.
[64] M. Manns,et al. Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting Polypeptide (NTCP) , 2015, PloS one.
[65] S. Urban,et al. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. , 2007, Hepatology.
[66] P. Sham,et al. The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B , 2015, Hepatology.
[67] C. Guguen-Guillouzo,et al. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. , 1995, Virology.
[68] Wenhui Li,et al. Viral Entry of Hepatitis B and D Viruses and Bile Salts Transportation Share Common Molecular Determinants on Sodium Taurocholate Cotransporting Polypeptide , 2014, Journal of Virology.
[69] S. Iwata,et al. Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT , 2011, Nature.
[70] C. Sureau. The role of the HBV envelope proteins in the HDV replication cycle. , 2006, Current topics in microbiology and immunology.
[71] W. Gerlich,et al. Large surface proteins of hepatitis B virus containing the pre-s sequence , 1984, Journal of virology.
[72] A. Geipel,et al. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. , 2014, Journal of hepatology.
[73] A. Budkowska,et al. Structural and functional characterization of a monoclonal antibody specific for the preS1 region of hepatitis B virus , 2001, FEBS letters.